MAT Resources

About MAT

- Benefits of MAT
- MAT for Opioid Use Disorder
- Opioid Overdose
- MAT for Alcohol Use Disorder
  - A Brief Guide
- Common Comorbidities
- Practitioner and Program Data
- Buprenorphine Practitioner Locator
- PCSS Mentoring Program
- Documentation and Charge Capture Process
- Business Plan for MAT
- Clinical Guidance for Treating Pregnant and Parenting Women with OUD and Their Infants
- SAMHSA MAT Guide for Pregnant Women with OUD
- Underuse of MAT
- MAT: The Best Therapy for OUD (video)
- Youth Opioid Addiction: A Part of Your Practice, So What Should You Know?
- Primer on Antagonist-Based Treatment of OUD in the Office Setting
- ASAM: Advancing Access to Addiction Medications
- Treatment Improvement Protocol (TIP) 63: Medications for OUD
- Clinical Advances in Non-Agonist Therapies
- Supporting Recovery with MAT (online course)
- ECHO Idaho Ongoing Opioid Resource List
- ECHO Idaho Opioid Series

Waiver Information

- Apply for a Practitioner Waiver
- Update Practitioner Contact Information
- Record Keeping Requirements
- Waiver Management in Spanish

Clinical Tools from PCSS

- Adherence, Diversion, and Misuse of Sublingual Buprenorphine
- Buprenorphine Induction
- Physician Billing for Office-Based Treatment of Opioid Use Disorder
- Other Resources
Clinical Forms from PCSS

- Sample Buprenorphine Patient Information
- Sample Buprenorphine Information for Family Members
- Sample Intake Questionnaire
- Sample Initial Patient Contact about Buprenorphine
- Sample Medical History and PE Form
- Sample Treatment Agreements (Version 1, 2, 3, and 4)
- Clinical Opiate Withdrawal Scale
- Modified OOWS Form
- Buprenorphine Stock Drug Accountability Record
- Buprenorphine Patient Log
- Progress Note Example
- Protocol for Follow-up Appointments
- Follow-up Appointments
- Billing Information
- How to Prepare for a DEA Inspection
- DEA Inspection References

Statutes, Regulations, and Guidelines

- DATA 2000
- Federal Regulation 42 CFR 8
- Model Guidelines for State Medical Boards
- The SUPPORT Act
- Special Circumstances for Providing Buprenorphine
- Understanding the Final Rule for a Patient Limit of 275
- American Congress of Obstetricians and Gynecologists (ACOG) Issues Guidelines on Opioid Use During Pregnancy
- The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine
- APA Issues Policy Statement on Pediatrics MAT
- ASAM National Practice Guidelines for the Use of Medications in the Treatment of OUD

MAT and Telemedicine

- DEA Information on Telemedicine
- Department of Justice Information on Use of Telemedicine While Providing MAT

Information for Pharmacists

- Verify Practitioner Waivers
- Buprenorphine Pharmacy Lookup
Opioid Treatment Program (OTP)

- Apply for OTP Certification
- Notify SAMHSA of Program Changes
- Submit an Opioid Treatment Exception Request
- OTP Compliance Officers
- Oversight of OTP Accrediting Bodies
  - Approved Accrediting Bodies

Methadone

- Pregnant or Breastfeeding Women and Methadone
- Childbirth, Breastfeeding and Infant Care: Methadone and Buprenorphine
- Pregnancy: Methadone and Buprenorphine
- Methadone and Buprenorphine: Opioid Agonist Substitution Tapers
- Negative Stigma of Methadone
- QTc Interval Screening in Methadone Treatment
- Drug Interactions of Clinical Importance with Methadone and Buprenorphine
- Indicators of Buprenorphine and Methadone Use and Abuse: What Do We Know?
- Drug-Drug Interactions in Opioid Therapy: A Focus on Buprenorphine and Methadone

Naltrexone

- Clinical Use of Extended-Release Injectable Naltrexone in the Treatment of OUD: A Brief Guide
- Preparation and Injection of Extended-Release Naltrexone (video)
- A Step-by-Step Guide
- Cost and Accessibility of Injection Naltrexone
- The Facts About Naltrexone (brochure)

Buprenorphine

- Diversion and Abuse of Buprenorphine
- Methadone and Buprenorphine: Opioid Agonist Substitution Tapers
- Childbirth, Breastfeeding and Infant Care: Methadone and Buprenorphine
- Pregnancy: Methadone and Buprenorphine
- Integration of Buprenorphine into HIV Primary Care Settings
- Drug Interactions of Clinical Importance with Methadone and Buprenorphine
- Indicators of Buprenorphine and Methadone Use and Abuse: What Do We Know?
- Drug-Drug Interactions in Opioid Therapy: A Focus on Buprenorphine and Methadone
- Buprenorphine Treatment: Training for Multidisciplinary Addiction Professionals
- Short-Term Opioid Withdrawal Using Buprenorphine
- Buprenorphine Treatment for Young Adults
Naloxone

- VA Releases Video Tutorials on Naloxone
- Resources on Narcan Prevention Kits

Language, Stigma, and Myths

- Misperceptions and the Misused Language of Addiction
- Language and Terminology Guidance for Journal of Addiction Medicine
- Words Matter Handout Created by Boston Medical Center
- Rethinking How We Talk About Addiction
- Negative Stigma of Methadone
- Myths and Misconceptions
- The Effectiveness of Interventions for Reducing Stigma Related to SUDs: A Systematic Review
- Changing the Language of Addiction
- Address Patient Shame, Stigma When Treating Opioid Misuse
- The Role of Shame in OUDs
- Confronting the Stigma of OUD and Its Treatment

MAT and COVID-19

- Opioid Treatment Program (OTP) Guidance
- OTP Guidance for Patients Quarantined at Home with Coronavirus
- Provision of Methadone and Buprenorphine for the Treatment of Opioid Use Disorder (OUD) during COVID
- Sample OTP COVID-19 FAQs
- Notification of Enforcement Discretion on Telehealth Remote Communications
- Use of Unregistered Off-Site Locations in MAT
- Use of Unregistered Off-Site Locations in Mat (Buprenorphine)
- Use of Telephone Evaluations to Initiate Buprenorphine Prescribing
- Exemption Allowing Alternate Delivery Methods for OTPs
- Q&A Methadone Shortages
- Distributor Shipments to NTP’s Signed Delivery Exception
- DEA Diversion Control Division COVID-19 Information

MAT and Perinatal Considerations from PCSS

- Childbirth, Breastfeeding, and Infant Care: Methadone and Buprenorphine
- Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants
- Pregnancy and Buprenorphine Treatment
- Pregnancy: Methadone and Buprenorphine